Study #2022-0860
An Open-Label phase I/II study to evaluate the safety and prelimiBasnary efficacy of amivantamab and tepotinib combination in MET-altered non-small cell lung cancer (NSCLC)
MD Anderson Study Status
Enrolling
Treatment Agent
Amivantamab, Tepotinib
Description
To learn if the combination of amivantamab and tepotinib can help to control NSCLC. The safety of this drug combination will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-small Cell Lung Cancer
Study phase:
Physician name:
Xiuning Le
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.